Abstract
We analyzed results of total antibodies to SARS-CoV-2 after receiving the booster dose of 3 different vaccines available in Serbia: BNT162b2 mRNA (Pfizer-BioNtech), Sinopharm BBIBP-CorV (Vero Cell®), GamCOVID-Vac (Sputnik V) from three blood samples for each of the 193 study participants drawn in intervals (before booster dose, 7 and 28 days after the booster dose). Sample analysis was performed with qualitative WANTAI ELISA immunoassay (BEING, CHINA). During the study period, there was a significant increase in total antibodies (B = 2.042; p < 0.001, e2 = 0.21). There was no significant difference between homologous and heterologous regimen booster immunization (B=-0.522; p=0.134). Thyroid diseases (B = -2.023) and age 65+ (B = -3.654) were independently associated with a lower level of total antibodies. These results suggest that regardless of COVID-19 vaccine types analyzed and the regimens applied, all vaccines provided benefits with the significant increase in total antibody levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
